Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >

Sjögren’s syndrome, which affects hundreds of millions of people worldwide, is a chronic autoimmune disorder characterized by leukocytic infiltration into the exocrine glands, such as the salivary and lacrimal glands. However, the pathological mechanism remains to be elucidated, and novel treatments are urgently needed. Over the past decade, extensive progress has been made in the …Read More >

Lung cancer is the leading cause of cancer-related death worldwide.  Nearly 80% of lung cancers are non-small cell lung cancer (NSCLC) and 60% of them are diagnosed at the metastatic stage. Brain metastases affect more than 20% of NSCLC patients with poor prognosis and disabling symptoms. However, few therapies have been approved for the treatment …Read More >

Non-CNS metastatic brain cancer is approximately 10 times more common than CNS cancer. Lung cancer and breast cancer account for most brain metastasis. KRAS-mutant NSCLC composes a third lung adenocarcinoma, among which 17% to 55% will develop brain metastases. Likewise, more than a third HER2-positive breast cancer will develop brain metastasis. Among existing animal models, …Read More >

The therapeutic landscape of cancer has been transformed over the last few decades. Our understanding of cancer and its therapeutic approach has improved greatly due to advanced cancer biology, functional imaging and next–generation sequencing. One of the key challenges in cancer therapy is how to effectively kill cancer cells while leaving normal cells intact. As …Read More >

The efficacy of immuno-oncology therapies needs to be evaluated in animal models with functional immune systems. Syngeneic tumor models are established by inoculating mouse cancer cell lines into immunocompetent mice with the same genetic background. The host mice have complete immune activity and show histocompatibility with homograft tumor tissues, which can maximize the simulation of …Read More >

We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including peptide vaccines, mRNA vaccines, DC vaccines and more. Ovalbumin (OVA) is a key model antigen which has been widely used in vaccination experiments. Here we established an OVA overexpressed system based on different types of …Read More >

We have established and optimized a robust tumor bone metastasis mouse model, which recapitulates the tumor metastasis progression from circulation to bone colonization, and provides a window for evaluating prophylaxis and treatment. Specifically, we inoculated two breast cancer cell lines, JIMT-1 and MDA-MB-231, each with high metastatic potential, into the mouse intra-caudal artery. By detection …Read More >